VENUSREM

Venus Remedies Share Price

 

 

Start SIP in VENUSREM

Start SIP

Performance

  • Low
  • ₹731
  • High
  • ₹754
  • 52 Week Low
  • ₹278
  • 52 Week High
  • ₹840
  • Open Price₹740
  • Previous Close₹737
  • Volume16,771
  • 50 DMA₹732.44
  • 100 DMA₹670.35
  • 200 DMA₹578.63

Investment Returns

  • Over 1 Month -1.65%
  • Over 3 Month + 31%
  • Over 6 Month + 58.13%
  • Over 1 Year + 135.8%

Smart Investing Starts Here Start SIP with Venus Remedies for Steady Growth!

Invest Now

Venus Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 13.1
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 1,001
  • P/B Ratio
  • 1.7
  • Average True Range
  • 41.3
  • EPS
  • 57.09
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.79
  • RSI
  • 49.47
  • MFI
  • 55.96

Venus Remedies Financials

Venus Remedies Technicals

EMA & SMA

Current Price
₹749.15
+ 11.85 (1.61%)
pointer
  • Bearish Moving Average 7
  • Bullish Moving Average 9
  • 20 Day
  • ₹752.54
  • 50 Day
  • ₹732.44
  • 100 Day
  • ₹670.35
  • 200 Day
  • ₹578.63

Resistance and Support

744.63 Pivot Speed
  • R3 781.02
  • R2 767.38
  • R1 758.27
  • S1 735.52
  • S2 721.88
  • S3 712.77

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Venus Remedies has an operating revenue of Rs. 699.88 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 11% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 35% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 12% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 71 which is a FAIR score but needs to improve its earnings, a RS Rating of 95 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Venus Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-29 Quarterly Results & Others To consider other business matters.
2025-11-10 Quarterly Results
2025-08-01 Quarterly Results
2025-07-08 Others Inter-alia, to consider 1. Notice of 36th Annual General Meeting. 2. Boards Report for Financial Year 2024-2025. 3. Other business matters.
2025-05-26 Audited Results

Venus Remedies F&O

Venus Remedies Shareholding Pattern

41.76%
2.25%
45.16%
10.83%

About Venus Remedies

  • NSE Symbol
  • VENUSREM
  • BSE Symbol
  • 526953
  • Chairman & Managing Director
  • Mr. Pawan Chaudhary
  • ISIN
  • INE411B01019

Similar Stocks to Venus Remedies

Venus Remedies FAQs

Venus Remedies share price is ₹749 As on 18 February, 2026 | 02:43

The Market Cap of Venus Remedies is ₹1001.4 Cr As on 18 February, 2026 | 02:43

The P/E ratio of Venus Remedies is 13.1 As on 18 February, 2026 | 02:43

The PB ratio of Venus Remedies is 1.7 As on 18 February, 2026 | 02:43

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23